AIDP, Inc. acquires core technology and related intellectual property on glant-based GOS from Olygose SAS
AIDP, Inc. announced that it has acquired the core technology and related intellectual property of Olygose SAS (France). This includes the transfer of patents, manufacturing technology, trademarks, but also pre-clinical and clinical studies, regulatory certificates, and other intellectual know-how.
Working closely with leading public academia and hospitals, Olygose has conducted 10 human clinical studies and 14 pre-clinical (in-vitro, ex-vivo and animal) studies. This research has resulted in 16 patents worldwide. The studies and patents focus on cardiometabolism and gut microbiota modulation.